Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 14/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18081172 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| SCHEMBL377976 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1480990 | 0.98 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15956717 | 0.98 | CHRNB2 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| SCHEMBL7050116 | 0.88 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4SMN1; SMN2 | |
| SCHEMBL28949604 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL26334441 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL6368277 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL2379324 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL2846979 | 0.80 | HTR2C (0.46) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473290-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL MYERS-SQUIBB COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3935058-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-114222744-B | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFNα response | 百时美施贵宝公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | disclosed |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | disclosed |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| CN-114222744-A | Imidazopyridazine compounds useful as IL-12, IL-23 and/or IFN alpha response modulators | 百时美施贵宝公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-3313397-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2020-11-25 | — | — | EP | disclosed |
| WO-2007113249-A2 | N-HYDROXY-3-(4-{3-PHENYL-S-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.R.L. (IT) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113249-A2 | N-HYDROXY-3-(4-{3-PHENYL-S-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.R.L. (IT) | 2007-10-11 | — | — | WO | disclosed |
| US-20070167444-A1 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| WO-2007033175-A1 | INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1632477-A1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | CHRNB2 2672/4885CHRNA3 1862/4885CHRNA4 1993/4885 |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, JAK3, IFNAR1 | CHRNB2 2320/4885CHRNA3 1896/4885CHRNA4 2832/4885 |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | HTR3C, IDO1, HTR3B | CHRNB2 1869/4885CHRNA3 1018/4885CHRNA4 1309/4885 |
| US-20070167444-A1 | Benzamide derivative or salt thereof | TRPV1, BDKRB1, BDKRB2 | CHRNB2 488/4885CHRNA3 675/4885CHRNA4 710/4885 |
| US-12473290-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | TYK2, JAK3, IFNAR1 | CHRNB2 2320/4885CHRNA3 1896/4885CHRNA4 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.